Developer docs
API playgroundTry for free, no card

Search company profiles

LUMICKS

Full company profile

uuid0000bx9

Namestring
LUMICKS
Legal namestring
LUMICKS Technologies B.V.
Websiteurl
lumicks.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

LUMICKS is a Netherlands-based life science tools company that develops and commercializes single-molecule and cell-cell interaction measurement platforms for academic research institutions and pharmaceutical/biotechnology companies in immuno-oncology and molecular biology. The company operates two complementary technology franchises: a Dynamic Single-Molecule platform centered on the C-Trap instrument, which uniquely combines optical tweezers with confocal fluorescence microscopy to manipulate and visualize individual molecular interactions in real time, supplemented by the lower-cost m-Trap; and a Cell Avidity platform built on z-Movi (ultrasonic force spectroscopy) and the newly launched Avidion high-throughput system, which measure the cumulative binding strength between immune cells and cancer cells to predict therapeutic efficacy in CAR-T, bispecific antibody and cell engager development. The company's underlying technology stack includes proprietary Acoustic Force Spectroscopy (AFS), the High-Throughput Avidity Measurement (HTAM) approach, and the Bluelake/Lakeview software stack for instrument control and data analysis, supported by consumables and reagents that generate recurring revenue.

LUMICKS monetizes through a direct enterprise sales motion targeting quote-based hardware sales of C-Trap, m-Trap, z-Movi and Avidion instruments, multi-year service contracts, recurring consumables and reagents, software licenses bundled with instruments, and professional services via the Avidigo offering. The company sells globally through regional offices in Amsterdam (HQ), Morrisville NC, Waltham MA, and Beijing, supported by Application Scientists, Account Managers, a scientific conference presence (SITC, CAR-TCR Summit, CICON, Biophysical Society), and a LUMICKS University customer community. Marquee customers include AstraZeneca (Cambridge Centre of Excellence), Dana-Farber Cancer Institute, Massachusetts General Hospital, University of Pennsylvania, Francis Crick Institute, Rockefeller University, Max Planck Institute, and a roster of cell therapy developers (Glycostem, Leucid Bio, LAVA Therapeutics, INmune Bio). The installed base exceeds 200 systems worldwide, backed by 230+ peer-reviewed user publications.

The company has raised approximately $113 million in total funding, including a $93 million Series D in April 2021 (led by Farallon Capital and Lauxera Capital Partners with SoftBank Vision Fund, T. Rowe Price, Gilde Healthcare and others) and a €20 million EIB venture debt facility in October 2024 backed by InvestEU. LUMICKS is privately held with no parent company, operates subsidiaries in the US and China, and is governed by a board with representation from SoftBank Vision Fund, Gilde Healthcare, Lauxera Capital Partners and Teich Technology Investments. Leadership was refreshed in 2024 with Hugo de Wit appointed CEO, joining co-founder Andrea Candelli (CSO), co-founder Gerrit Sitters (Head of Product), CFO Edmee Verhulp and CCO Paul Wheeler. All products are Research Use Only (RUO), and LUMICKS is not ISO certified at the company level.

Short descriptiontext

LUMICKS is a Netherlands-based life science tools company that develops single-molecule and cell avidity measurement platforms — including the C-Trap optical tweezers microscope, z-Movi, and Avidion instruments — serving academic research institutions and pharmaceutical/biotech customers in immuno-oncology and molecular biology drug development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAmsterdam, Netherlands
HQ citystring
Amsterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-molecule analysis, cell avidity measurement, force spectroscopy instruments, immuno-oncology research tools, biophysics research equipment
Industry3 codes
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Life Science Instruments
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Scientific Instrumentation Hardware
TypeHardware Sales
Description

Sale of C-Trap, m-Trap, z-Movi, and Avidion instruments along with associated modules and configurations. Instruments range from entry-level m-Trap to advanced multi-color C-Trap systems.

lumicks.com
2Consumables and Reagents
TypeHardware Sales
Description

Recurring revenue from microfluidic chips, optical trap beads, and specialized reagents required for instrument operation.

lumicks.com
3Software Licenses
TypeSubscription Recurring
Description

Software products including Bluelake and Lakeview analysis platforms bundled with instrument purchases.

lumicks.com
4Avidigo Services
TypeProfessional Services
Description

White-glove professional services for Cell Avidity experiments, providing expert support for customers.

lumicks.com
5LUMICKS University Training
TypeProfessional Services
Description

Educational programs, workshops, and summer schools for single-molecule analysis techniques.

lumicks.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Infrastructure
Pricing details1 tier
1Quote-based enterprise instrumentation pricing
ModelOtherBilling cadenceMulti-year contract
Notes

C-Trap, m-Trap, z-Movi, and Avidion instruments sold via direct sales with custom configurations. Pricing varies by instrument type, channel configuration (1-color, 2-color, 3-color confocal), and optional modules. Annual service contracts available.

lumicks.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1z-Movi
Description

Cell avidity analyzer for measuring binding strength between cells in immuno-oncology research

lumicks.com
+5 more records
Core offering1 text field

LUMICKS develops and manufactures Dynamic Single-Molecule and Cell Avidity analysis instruments (C-Trap, m-Trap, z-Movi, Avidion) that combine optical tweezers with fluorescence microscopy and ultrasonic force spectroscopy to enable real-time manipulation and visualization of molecular and cellular binding interactions. The company sells these proprietary instruments along with associated consumables, software (Bluelake, Lakeview), and white-glove services (Avidigo) to academic research institutions and pharmaceutical/biotech companies developing immuno-oncology and molecular biology therapeutics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Cell Avidity is the only pre-clinical assay that correlates with in vivo results in CAR-T development
+3 more records
Product overview1 text field

LUMICKS is a life science tools company offering two main technology platforms: (1) Cell Avidity solutions comprising Avidion (high-throughput next-generation platform) and z-Movi (for smaller Cell Avidity studies), both measuring the combined strength of cell-cell and cell-protein binding for immuno-oncology research including cell therapy, cell engagers, and antibody therapy development; and (2) Dynamic Single-Molecule technology centered on the C-Trap instrument, which combines optical tweezers with fluorescence microscopy to enable real-time manipulation and visualization of single-molecule interactions for molecular biology research. The portfolio is supported by software tools (Bluelake, Lakeview), consumables, and Avidigo service offerings.

Product and service5 records
1Avidion
CategoryCell Avidity Instrument
Description

Next-generation high-throughput Cell Avidity platform for cell therapy development, providing automated workflow and intuitive software to measure cell-cell and cell-protein binding strength for immunotherapy research.

2z-Movi Cell Avidity Analyzer
CategoryCell Avidity Instrument
Description

Instrument using ultrasonic force spectroscopy to measure the strength of interactions between immune cells and target cells at single-cell resolution, used for CAR-T, cell engager, and antibody therapy development.

3C-Trap
CategorySingle-Molecule Instrument
Description

Dynamic single-molecule microscope combining optical tweezers with fluorescence microscopy to enable simultaneous manipulation and visualization of single-molecule interactions in real-time for molecular biology research.

4m-Trap
CategorySingle-Molecule Instrument
Description

Single-molecule force spectroscopy instrument developed to lower the barrier to advanced single-molecule analysis without compromising performance, used for kinetochore-microtubule binding and related research.

5Avidigo Services
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Biomedical Science Research and Training Centre (BioRTC) and Trend In Africa
Strategic tierMinorTypeOthersAnnounced on2023-05-26
Description

Equipment donation program supporting biomedical science education in Nigeria. BioRTC collects unused equipment for Nigerian labs.

lumicks.com
2Scientific Advisory Board Members
Strategic tierCoreTypeOthersAnnounced on2021-12-15
Description

World-renowned scientists and business executives including Marcela Maus (MGH), Marco Ruella (UPenn), and Mathieu Ferrari (Autolus) advising on science and technology.

lumicks.com
3First Center of Excellence for Brain and Disease Research
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-28
Description

First Center of Excellence for Dynamic Single-Molecule Studies for Brain and Disease Research established in Belgium.

lumicks.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-07-22
Description

INmune Bio acquired z-Movi Cell Avidity Analyzer to accelerate selection of NK cell products for cancer treatments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-04
Description

Collaboration to characterize tumor-specific gamma-delta T-cell engagers using LUMICKS' cell avidity technology for immuno-oncology research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-10-30
Description

Strategic collaboration to evaluate next-generation pCARs (protein-based CARs) using cell avidity analysis to optimize therapeutic candidates.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-07-30
Description

Collaboration to enhance NK cell-mediated immunotherapy using LUMICKS' z-Movi Cell Avidity technology for characterizing NK cell binding properties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-06-27
Description

Centre of Excellence in Dynamic Single-Molecule Analysis for Accelerated Drug Discovery. Joint collaboration to advance drug discovery using LUMICKS' C-Trap technology.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major microscopy and imaging systems company offering confocal, super-resolution, and live-cell imaging platforms. Overlaps with LUMICKS' C-Trap dynamic single-molecule instrument in advanced optical microscopy applications for life sciences.

TypeBroad incumbent
Description

Major life science tools and bioprocessing company with cell analysis, cell line development, and immuno-oncology workflow products. LUMICKS' new CEO Hugo de Wit previously headed Sartorius' Cell Culture Technologies business, illustrating the talent flow and competitive overlap between the two companies.

TypeBroad incumbent
Description

Provides analytical instruments for particle characterization, molecular size, and biophysical properties. Comparable to LUMICKS' dynamic single-molecule and force spectroscopy capabilities as a broader portfolio provider serving biophysics and protein characterization markets.

4PhenomeX (formerly Berkeley Lights)
TypeDirect peer
Description

Developed optofluidic platforms (Beacon) for live-cell manipulation and functional screening at single-cell resolution. Directly comparable to LUMICKS in the single-cell, light-based manipulation category, though with a different application focus (cell line development vs. immuno-oncology).

TypeEmerging player
Description

Single-cell proteomics and functional profiling platform for characterizing immune cell behavior and cell therapy products. Addresses overlapping immuno-oncology and CAR-T development workflows as LUMICKS' cell avidity platform, with a complementary proteomics angle.

6Carl Zeiss Microscopy
TypeBroad incumbent
Description

Dominant microscopy and imaging systems provider with advanced super-resolution and live-cell imaging platforms (LSM, Elyra, etc.). Competes broadly with LUMICKS' C-Trap in advanced fluorescence microscopy applications for cell biology and biophysics research.

TypeDirect peer
Description

Provides mass cytometry and single-cell analysis instrumentation (Helios, Hyperion imaging mass cytometry) for immuno-oncology research. Competes in the same translational research market as LUMICKS, particularly for cell therapy and immunology applications.

TypeDirect peer
Description

Specializes in biophysical characterization instruments (Monolith, Prometheus, Tycho) for protein stability, binding affinity, and interaction analysis. Comparable to LUMICKS in serving protein science and drug discovery researchers with benchtop biophysical tools, though with a different measurement modality.

TypeEmerging player
Description

Specializes in spectral flow cytometry with the Aurora and Northern Lights systems for high-parameter cell analysis. Addresses overlapping immuno-oncology and cell therapy customers as LUMICKS' z-Movi and Avidion, with a broader application footprint.

TypeDirect peer
Description

Large life science instrumentation company with optical tweezers products (e.g., optical tweezers modules for single-molecule force spectroscopy) and biophysical characterization tools. Directly competes with LUMICKS in single-molecule and biophysics markets, and has the scale and channel reach to pressure LUMICKS in pharma accounts.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LUMICKS

Life Science Instrumentslumicks.com

LUMICKS is a Netherlands-based life science tools company that develops single-molecule and cell avidity measurement platforms — including the C-Trap optical tweezers microscope, z-Movi, and Avidion instruments — serving academic research institutions and pharmaceutical/biotech customers in immuno-oncology and molecular biology drug development.

What LUMICKS does

LUMICKS is a Netherlands-based life science tools company that develops and commercializes single-molecule and cell-cell interaction measurement platforms for academic research institutions and pharmaceutical/biotechnology companies in immuno-oncology and molecular biology. The company operates two complementary technology franchises: a Dynamic Single-Molecule platform centered on the C-Trap instrument, which uniquely combines optical tweezers with confocal fluorescence microscopy to manipulate and visualize individual molecular interactions in real time, supplemented by the lower-cost m-Trap; and a Cell Avidity platform built on z-Movi (ultrasonic force spectroscopy) and the newly launched Avidion high-throughput system, which measure the cumulative binding strength between immune cells and cancer cells to predict therapeutic efficacy in CAR-T, bispecific antibody and cell engager development. The company's underlying technology stack includes proprietary Acoustic Force Spectroscopy (AFS), the High-Throughput Avidity Measurement (HTAM) approach, and the Bluelake/Lakeview software stack for instrument control and data analysis, supported by consumables and reagents that generate recurring revenue.

LUMICKS monetizes through a direct enterprise sales motion targeting quote-based hardware sales of C-Trap, m-Trap, z-Movi and Avidion instruments, multi-year service contracts, recurring consumables and reagents, software licenses bundled with instruments, and professional services via the Avidigo offering. The company sells globally through regional offices in Amsterdam (HQ), Morrisville NC, Waltham MA, and Beijing, supported by Application Scientists, Account Managers, a scientific conference presence (SITC, CAR-TCR Summit, CICON, Biophysical Society), and a LUMICKS University customer community. Marquee customers include AstraZeneca (Cambridge Centre of Excellence), Dana-Farber Cancer Institute, Massachusetts General Hospital, University of Pennsylvania, Francis Crick Institute, Rockefeller University, Max Planck Institute, and a roster of cell therapy developers (Glycostem, Leucid Bio, LAVA Therapeutics, INmune Bio). The installed base exceeds 200 systems worldwide, backed by 230+ peer-reviewed user publications.

The company has raised approximately $113 million in total funding, including a $93 million Series D in April 2021 (led by Farallon Capital and Lauxera Capital Partners with SoftBank Vision Fund, T. Rowe Price, Gilde Healthcare and others) and a €20 million EIB venture debt facility in October 2024 backed by InvestEU. LUMICKS is privately held with no parent company, operates subsidiaries in the US and China, and is governed by a board with representation from SoftBank Vision Fund, Gilde Healthcare, Lauxera Capital Partners and Teich Technology Investments. Leadership was refreshed in 2024 with Hugo de Wit appointed CEO, joining co-founder Andrea Candelli (CSO), co-founder Gerrit Sitters (Head of Product), CFO Edmee Verhulp and CCO Paul Wheeler. All products are Research Use Only (RUO), and LUMICKS is not ISO certified at the company level.

LUMICKS firmographics

Firmographics
Name
LUMICKS
Legal name
LUMICKS Technologies B.V.
Website
https://lumicks.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
LUMICKS is a Netherlands-based life science tools company that develops single-molecule and cell avidity measurement platforms — including the C-Trap optical tweezers microscope, z-Movi, and Avidion instruments — serving academic research institutions and pharmaceutical/biotech customers in immuno-oncology and molecular biology drug development.
Ownership category
akta.pro rank

LUMICKS industry classification

Industry
Product category
Life Science Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)

Keywords

  • Single-molecule analysis
  • Cell avidity measurement
  • Force spectroscopy instruments
  • Immuno-oncology research tools
  • Biophysics research equipment

Where LUMICKS is headquartered

Location

Headquarters

HQ city
Amsterdam
HQ country
Netherlands
HQ region
Europe

Offices4 records

Markets served

LUMICKS business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

  1. Scientific Instrumentation Hardware: Sale of C-Trap, m-Trap, z-Movi, and Avidion instruments along with associated modules and configurations. Instruments range from entry-level m-Trap to advanced multi-color C-Trap systems.
  2. Consumables and Reagents: Recurring revenue from microfluidic chips, optical trap beads, and specialized reagents required for instrument operation.
  3. Software Licenses: Software products including Bluelake and Lakeview analysis platforms bundled with instrument purchases.
  4. Avidigo Services: White-glove professional services for Cell Avidity experiments, providing expert support for customers.
  5. LUMICKS University Training: Educational programs, workshops, and summer schools for single-molecule analysis techniques.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise instrumentation pricing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

LUMICKS product offering

Product offering

Core offering

LUMICKS develops and manufactures Dynamic Single-Molecule and Cell Avidity analysis instruments (C-Trap, m-Trap, z-Movi, Avidion) that combine optical tweezers with fluorescence microscopy and ultrasonic force spectroscopy to enable real-time manipulation and visualization of molecular and cellular binding interactions. The company sells these proprietary instruments along with associated consumables, software (Bluelake, Lakeview), and white-glove services (Avidigo) to academic research institutions and pharmaceutical/biotech companies developing immuno-oncology and molecular biology therapeutics.

Product overview

LUMICKS is a life science tools company offering two main technology platforms: (1) Cell Avidity solutions comprising Avidion (high-throughput next-generation platform) and z-Movi (for smaller Cell Avidity studies), both measuring the combined strength of cell-cell and cell-protein binding for immuno-oncology research including cell therapy, cell engagers, and antibody therapy development; and (2) Dynamic Single-Molecule technology centered on the C-Trap instrument, which combines optical tweezers with fluorescence microscopy to enable real-time manipulation and visualization of single-molecule interactions for molecular biology research. The portfolio is supported by software tools (Bluelake, Lakeview), consumables, and Avidigo service offerings.

Differentiator

Problem solved

Functional benefit

Brands

  • z-Movi: Cell avidity analyzer for measuring binding strength between cells in immuno-oncology research
  • Avidion
  • C-Trap
  • m-Trap
  • Lakeview
  • Bluelake

Products and services

  • Avidion Next-generation high-throughput Cell Avidity platform for cell therapy development, providing automated workflow and intuitive software to measure cell-cell and cell-protein binding strength for immunotherapy research.
  • z-Movi Cell Avidity Analyzer Instrument using ultrasonic force spectroscopy to measure the strength of interactions between immune cells and target cells at single-cell resolution, used for CAR-T, cell engager, and antibody therapy development.
  • C-Trap Dynamic single-molecule microscope combining optical tweezers with fluorescence microscopy to enable simultaneous manipulation and visualization of single-molecule interactions in real-time for molecular biology research.
  • m-Trap Single-molecule force spectroscopy instrument developed to lower the barrier to advanced single-molecule analysis without compromising performance, used for kinetochore-microtubule binding and related research.
  • Avidigo Services

Quantifiable outcome

  • Cell Avidity is the only pre-clinical assay that correlates with in vivo results in CAR-T development
  • +3 more outcomes

Companies that use LUMICKS

Customer profile

Named customers14 records

Segments4 records

Ideal customer profiles3 records

LUMICKS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

LUMICKS partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • Biomedical Science Research and Training Centre (BioRTC) and Trend In AfricaminorOthers · 26 May 2023Equipment donation program supporting biomedical science education in Nigeria. BioRTC collects unused equipment for Nigerian labs.
  • Scientific Advisory Board MemberscoreOthers · 15 December 2021World-renowned scientists and business executives including Marcela Maus (MGH), Marco Ruella (UPenn), and Mathieu Ferrari (Autolus) advising on science and technology.
  • First Center of Excellence for Brain and Disease ResearchcoreStrategic or Co-development Partner · 28 July 2021First Center of Excellence for Dynamic Single-Molecule Studies for Brain and Disease Research established in Belgium.
  • INmune BiocoreTechnology or Integration · 22 July 2021INmune Bio acquired z-Movi Cell Avidity Analyzer to accelerate selection of NK cell products for cancer treatments.
  • LAVA TherapeuticscoreStrategic or Co-development Partner · 4 December 2020Collaboration to characterize tumor-specific gamma-delta T-cell engagers using LUMICKS' cell avidity technology for immuno-oncology research.
  • Leucid BiocoreStrategic or Co-development Partner · 30 October 2020Strategic collaboration to evaluate next-generation pCARs (protein-based CARs) using cell avidity analysis to optimize therapeutic candidates.
  • GlycostemcoreStrategic or Co-development Partner · 30 July 2020Collaboration to enhance NK cell-mediated immunotherapy using LUMICKS' z-Movi Cell Avidity technology for characterizing NK cell binding properties.
  • AstraZeneca and University of CambridgecoreStrategic or Co-development Partner · 27 June 2018Centre of Excellence in Dynamic Single-Molecule Analysis for Accelerated Drug Discovery. Joint collaboration to advance drug discovery using LUMICKS' C-Trap technology.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

LUMICKS competitors and assessment

Company assessment

Broad incumbents

  • Leica Microsystems (Danaher): Major microscopy and imaging systems company offering confocal, super-resolution, and live-cell imaging platforms. Overlaps with LUMICKS' C-Trap dynamic single-molecule instrument in advanced optical microscopy applications for life sciences.
  • Sartorius: Major life science tools and bioprocessing company with cell analysis, cell line development, and immuno-oncology workflow products. LUMICKS' new CEO Hugo de Wit previously headed Sartorius' Cell Culture Technologies business, illustrating the talent flow and competitive overlap between the two companies.
  • Malvern Panalytical: Provides analytical instruments for particle characterization, molecular size, and biophysical properties. Comparable to LUMICKS' dynamic single-molecule and force spectroscopy capabilities as a broader portfolio provider serving biophysics and protein characterization markets.
  • Carl Zeiss Microscopy: Dominant microscopy and imaging systems provider with advanced super-resolution and live-cell imaging platforms (LSM, Elyra, etc.). Competes broadly with LUMICKS' C-Trap in advanced fluorescence microscopy applications for cell biology and biophysics research.

Direct peers

  • PhenomeX (formerly Berkeley Lights): Developed optofluidic platforms (Beacon) for live-cell manipulation and functional screening at single-cell resolution. Directly comparable to LUMICKS in the single-cell, light-based manipulation category, though with a different application focus (cell line development vs. immuno-oncology).
  • Standard BioTools (formerly Fluidigm): Provides mass cytometry and single-cell analysis instrumentation (Helios, Hyperion imaging mass cytometry) for immuno-oncology research. Competes in the same translational research market as LUMICKS, particularly for cell therapy and immunology applications.
  • NanoTemper Technologies: Specializes in biophysical characterization instruments (Monolith, Prometheus, Tycho) for protein stability, binding affinity, and interaction analysis. Comparable to LUMICKS in serving protein science and drug discovery researchers with benchtop biophysical tools, though with a different measurement modality.
  • Bruker: Large life science instrumentation company with optical tweezers products (e.g., optical tweezers modules for single-molecule force spectroscopy) and biophysical characterization tools. Directly competes with LUMICKS in single-molecule and biophysics markets, and has the scale and channel reach to pressure LUMICKS in pharma accounts.

Emerging players

  • IsoPlexis: Single-cell proteomics and functional profiling platform for characterizing immune cell behavior and cell therapy products. Addresses overlapping immuno-oncology and CAR-T development workflows as LUMICKS' cell avidity platform, with a complementary proteomics angle.
  • Cytek Biosciences: Specializes in spectral flow cytometry with the Aurora and Northern Lights systems for high-parameter cell analysis. Addresses overlapping immuno-oncology and cell therapy customers as LUMICKS' z-Movi and Avidion, with a broader application footprint.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

LUMICKS social profiles

Digital presence

LUMICKS compliance and trust

Trust signal

Compliance2 records

LUMICKS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LUMICKS leadership team

Management profile

Number of profiles

Profiles5 records

LUMICKS subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

LUMICKS funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LUMICKS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LUMICKS

What does LUMICKS do?

LUMICKS develops and manufactures Dynamic Single-Molecule and Cell Avidity analysis instruments (C-Trap, m-Trap, z-Movi, Avidion) that combine optical tweezers with fluorescence microscopy and ultrasonic force spectroscopy to enable real-time manipulation and visualization of molecular and cellular binding interactions. The company sells these proprietary instruments along with associated consumables, software (Bluelake, Lakeview), and white-glove services (Avidigo) to academic research institutions and pharmaceutical/biotech companies developing immuno-oncology and molecular biology therapeutics.

Is LUMICKS a public or private company?

LUMICKS is a private company. It is classified as venture growth investor backed and is currently operating.

When was LUMICKS founded?

LUMICKS was founded in 2013. It employs 101 to 250 people.

Where is LUMICKS based?

LUMICKS is headquartered in Amsterdam, Netherlands, in the Europe region.

How does LUMICKS make money?

Five revenue lines are on record. Scientific Instrumentation Hardware is the primary driver. The others are consumables and Reagents, software Licenses, avidigo Services and LUMICKS University Training.

Who are LUMICKS's main competitors?

Broad incumbents on record are Leica Microsystems (Danaher), Sartorius, Malvern Panalytical and Carl Zeiss Microscopy. Direct peers are PhenomeX (formerly Berkeley Lights), Standard BioTools (formerly Fluidigm), NanoTemper Technologies and Bruker. Emerging players are IsoPlexis and Cytek Biosciences.

Does LUMICKS have an API?

No public API is recorded for LUMICKS.

What industry is LUMICKS in?

LUMICKS's product category is Life Science Instruments. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireLUMICKS launches Avidion to improve cell therapy developmentLUMICKS announced the European launch of Avidion, a next-generation Cell Avidity platform, at CICON 2025 in Utrecht, The Netherlands on September 10-12. The platform addresses the critical gap between molecular binding assays and functional outcome measurements, targeting the 83% failure rate of CAR-T cell therapies after preclinical development. Avidion features high-throughput compatibility with standard 96-well plates, fully automated operation enhanced by machine learning, and aims to improve preclinical success rates and reduce overall development costs for cell therapies.LumicksDutch Life Science Tools LUMICKS secures €20 million from European Investment Bank to accelerate drug discovery for cancerDutch life science tools company LUMICKS secured a €20 million venture debt agreement from the European Investment Bank (EIB) to accelerate the launch of its high-throughput cell avidity platform. The financing, supported by the European Commission’s InvestEU initiative, aims to advance drug discovery for cancer immunotherapy by replacing traditional screening methods with more reliable cellular interaction measurements.AgenparlDutch Life Science Tools LUMICKS secures €20 million from European Investment Bank to accelerate drug discovery for cancer.Dutch life science tools company LUMICKS secured a €20 million venture debt agreement from the European Investment Bank (EIB) to accelerate the development and launch of its new high-throughput cell avidity platform. Backed by the European Commission's InvestEU initiative, this funding aims to enhance cancer immunotherapy drug discovery by replacing traditional screening methods with more reliable measurement tools.Silicon CanalsAmsterdam’s LUMICKS gets €20M from EIBAmsterdam-based life science tools company LUMICKS secured €20 million in venture debt from the European Investment Bank (EIB), backed by the European Commission's InvestEU initiative. The funding will be used to launch a next-generation, high-throughput cell avidity platform designed to accelerate R&D and improve cancer immunotherapy development.EibNederlands med-techbedrijf LUMICKS leent €20 miljoen van EIB om ontdekking van nieuwe geneesmiddelen tegen kanker te versnellen.LUMICKS, a med-tech company based in Amsterdam, has signed a €20 million loan agreement with the European Investment Bank (EIB) to develop and launch a new cell avidity platform intended to accelerate cancer immunotherapy drug discovery. The funding, supported by the European Commission’s InvestEU program, aims to enhance the speed and reliability of the drug discovery process by enabling direct measurement of immune cell interactions with cancer cells. This investment underscores the EIB's commitment to bolstering medical innovation within the vibrant Dutch biomedical sector.PR NewswireCancer Cell Paper Identifies "Avidity Enhancement" As New Strategy for Improving CAR T Therapy for Acute Myeloid LeukemiaLUMICKS announced the publication of preclinical research in Cancer Cell identifying "Avidity Enhancement" as a new strategy to improve CAR T cell immunotherapy efficacy for Acute Myeloid Leukemia, a disease that causes approximately 20,000 deaths annually in the US and 300,000 worldwide. The study, authored by researchers led by Dr. Marcela V. Maus at Harvard Medical School and Massachusetts General Hospital, demonstrated that increasing cell-cell binding between CAR T cells and tumor cells using LUMICKS' z-Movi Cell Avidity Analyzer led to superior tumor clearance in mouse models compared to standard in vitro assays. This research builds on prior findings from the same lab identifying "avidity escape" as a tumor evasion mechanism, suggesting that avidity manipulation could be a crucial biomarker for selecting more effective immunotherapies in both hematological malignancies and solid tumors.PR NewswireLUMICKS Appoints Andre Nel as Chief Financial OfficerLUMICKS appointed Andre Nel as Chief Financial Officer, based in Amsterdam. He brings over 20 years of experience, including CFO roles at Dante Labs, Illumina, and Pfizer. The company expects his expertise to support its global growth plans.PR NewswireLUMICKS Appoints Andre Nel as Chief Financial OfficerLUMICKS, a leading life science tools company headquartered in Amsterdam, announced the appointment of Andre Nel as Chief Financial Officer. Nel brings over 20 years of experience from global life sciences companies including Illumina, Pfizer, and Dante Labs, and is expected to help scale the company's operations worldwide. The appointment aligns with LUMICKS' recent product launches and growth trajectory in the dynamic single-molecule and cell avidity analysis markets.PR NewswireNature Paper Identifies "Avidity Escape" As Solid Tumor Evasion Mechanism of CAR T Cell Cancer TherapiesA landmark study published in Nature by researchers at Massachusetts General Hospital, Harvard Medical School, and the Broad Institute of MIT and Harvard has identified "avidity escape" as a new mechanism through which solid tumors evade CAR T cell therapies, demonstrating that tumor cells avoid killing by down-regulating the adhesion strength between effector immune cells and their targets. The research utilized LUMICKS' z-Movi® Cell Avidity Analyzer to measure cell avidity and found that loss of interferon-γ receptor (IFNγR) signaling reduced binding between CAR T cells and solid tumor cells, determining insufficient cell avidity as the mechanism underpinning poor therapeutic outcomes. The study suggests that incorporating cell avidity measurements into CAR T cell development programs could reduce failure rates in solid tumor clinical trials and inform next-generation drug designs that optimize binding interactions.PR NewswireLUMICKS Strengthens its Innovative C-Trap® Solution with Launch of New Lakeview Analysis Software PlatformLUMICKS announced Lakeview, a new software platform for analyzing C-Trap instrument data, to simplify data analysis for researchers. The platform will launch at Experimental Biology 2022 in Philadelphia and aims to democratize access to dynamic single-molecule analysis. It integrates with LUMICKS' consumable offerings to produce quantitative results.